PETACH TIKVA, ISRAEL -- (Marketwired) -- 09/23/13 -- Can-Fite BioPharma (TASE: CFBI), (PINKSHEETS: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Company's CEO Dr. Pnina Fishman was recently interviewed on CorporateProfile.com.
In the interview Dr. Fishman spoke about Can-Fite listing its shares in the U.S., the Company's drug development pipeline, and the scientific basis for Can-Fite's platform technology.
To view the interview in full please visit: http://www.corporateprofile.com/2013/09/20/interview-with-can-fite-biopharma-canfy-ceo-dr-pnina-fishman/
Can-Fite is currently conducting Phase II and Phase III trials in the U.S., Europe and Israel for five indications in cancer, autoimmune inflammatory disease, and ophthalmology, which together serve multi-billion dollar markets. The Company's CR102 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of liver cancer. Can-Fite also owns 82% of OphthaliX Inc., which is currently traded on the U.S. markets (OTCQB: OPLI).
About Corporate Profile®
Corporate Profile® is a multi-media news provider, creating original daily news segments and interviews covering topics including finance, fashion, medicine, charitable causes, lifestyle, and wellness through www.corporateprofile.com. Financial segments are broadcast on www.cpreports.com, which provides viewers and readers fresh, original, and highly informative ideas and market commentary from Wall Street.
About Can-Fite Biopharma Ltd.
Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). Level II American Depository Receipts of the company are traded on the over-the-counter market (OTCQB: CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman's scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a controlling interest (OTCQB: OPLI).
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Can-Fite's business can be found in its periodic filings with the Tel Aviv Stock Exchange.
|Can-Fite CEO to Ring Opening Bell at New York Stock Exchange (2013/12/2)|
|Can-Fite CEO Issues Letter to Shareholders (2013/12/11)|
|T3 Motion CEO William Tsumpes Interviewed on Clear Channel Business Talk Radio PART-2 ()|
|Sport Chalet's Chairman and CEO Craig Levra Interviewed by The Wall Street Transcript (2013/9/20)|
|T3 Motion CEO William Tsumpes Interview on Clear Channel Business Talk Radio DFW1190AM Michael Yorba (2013/11/8)|
|Xerium President and CEO Harold Bevis Interviewed by China Pulp & Paper Industry Magazine (2013/8/28)|
|Harvard Apparatus Regenerative Technology CEO David Green Interviewed on Bloomberg Television (2014/3/27)|
|CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months (2014/2/11)|
|TheDirectory.com CEO to Be Interviewed on Small Cap Stock Program Traders Nation (2013/8/2)|
|AxoGen CEO Karen Zaderej Interview on Clear Channel Business Talk Radio DFW1190AM by Michael Yorba ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.